Skip Navigation

Lotus announces strategic partnership with Teraju Pharma in Malaysia

09 June 2023

Taipei, Taiwan, June 9th , 2023 -- Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced today that Lotus and Teraju Pharma, a leading pharmaceutical company based in Malaysia, have entered into a strategic partnership for the Malaysian market. Teraju has an extensive commercial reach in Malaysia and sources a broad range of branded or generic equivalent medicines from all over the world to fulfill the needs of the local market. This partnership allows Teraju to market and promote Lotus’ branded products across various therapeutic areas utilizing Teraju’s extensive infrastructure and broad relationships.

The collaboration is in-line with Lotus’ strategic plan to expand in Southeast Asia and the partnership plans to launch a portfolio of products beginning in the fourth quarter of 2023 in the therapeutic categories of oncology, cardio-metabolic and ophthalmology. These fast-tracked launches are expected to give an immediate boost to Lotus’ presence in Malaysia. According to IQVIA data, the overall market size of the selected products is USD 12 Million and has experienced strong growth over the last 5 years.

Petar Vazharov, Lotus’ Chief Executive Officer, said: “We are delighted at our new collaboration with Teraju.  This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and rich pipeline of products.”


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. 


About Teraju

Teraju Pharma Sdn Bhd started its journey in 2015 with a clear mission to provide accessibility to products and services in the local and regional community. Its four core services include: global drug sourcing, warehouse and company, sales and marketing, and pharmacy benefit management.

Through commitment to innovation, Teraju Pharma prides itself on being a leader of pharmaceutical supply-chain solutions in the Southeast Asian region.




Media Enquiries:

Susan Liao, IR/PR Director

+886 2 2700 5908